🇺🇸 FDA
Patent

US 9789096

Methods and compositions for selective and targeted cancer therapy

granted A61KA61K31/381A61K31/426

Quick answer

US patent 9789096 (Methods and compositions for selective and targeted cancer therapy) held by The Board of Regents of the University of Texas System expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/381, A61K31/426, A61K31/428, A61P